The complicated relationship between GLP-1s and pregnancy
A new study sheds light on the risks and benefits of taking GLP-1 weight-loss drugs before having a baby.
People who stop using Mounjaro tend to regain weight and lose other health benefits, says study
Improvements such as reduced ‘bad’ cholesterol and lower blood pressure go into reverse upon stopping weight-loss jabsPeople who stop using the weight-loss jab Mounjaro not only tend to regain weight, but experience a reversal in other health improvements too, research suggests.Mounjaro, which contains the active ingredient tirzepatide, has become a popular medication for weight loss, with studies suggesting that it can help people lose an average of 20% of their body weight after 72 weeks of treatment. Continue reading…
STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! We’re closing in on CMS’s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent in how the FDA selects priority review vouchers, and more. Can a GLP-1 drug slow Alzheimer’s […]
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
Eli Lilly LLY briefly crossed the $1 trillion market cap on Nov. 21, 2025 — becoming the first-ever health-care company to join the elite group mainly dominated by tech giants, as mentioned on CNBC. Shares touched around $1,059 on the day. GLP-1 &GIP Leadership Fuels Rally The stock has surged 36.2% this year, mainly backed by […]
Thinking about weight-loss jabs but fear the side effects? Try these miracle foods dubbed ‘nature’s Ozempic’ that produce GLP-1 BEFORE you book that telehealth appointment
‘What if I told you that you can introduce foods into your diet that help the body increase its natural production of GLP-1? Foods you can enjoy that have no side effects …’
NVO US
NVO US Novo Nordisk A/S Sponsored ADR Class B BATS:NVO A3MInvestments The decline in Novo Nordisk shares is not the result of a single factor, but rather the result of a complex set of fundamental issues: weakening financial performance, loss of competitive advantage in key products, and increased strategic risks. While negative data on Eli […]
A Healthy Dose Of Competition Sends Weight-Loss Drug Prices Plummeting
Novo and Lilly just slashed prices on GLP-1 weight-loss drugs that recently cost over $1,000 a month. What happened?
Pharmalittle: We’re reading about failed Novo Alzheimer’s trials, favorable Bayer stroke results, and more
Good morning, Jason Mast here filling in for Ed. Happy turkey week to all. I, for one, have always detested that dry, tasteless bird. (It’s sides and brisket for me, followed by pecan pie.) So in their interest, I leave you with this story, from 2018, about the Ozark turkeys that fell from the sky. […]
Novo Nordisk says Alzheimer’s drug trial fails to meet main goal
Novo Nordisk’s shares fell 10% after the company said its oral semaglutide drug Rybelsus failed to meet the main goal in late-stage trials testing whether it could slow cognitive decline in early Alzheimer’s patients. The setback dims hopes for expanding GLP-1 medicines into a major new market beyond obesity and diabetes, reinforcing scepticism over Novo’s […]
诺和诺德能否凭借GLP-1的阿尔茨海默病数据终结礼来股价上涨势头 – Seeking Alpha
Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1 (news.google.com) 11-23 #Seeking Alpha